This company has been marked as potentially delisted and may not be actively trading. NASDAQ:AKLI Akili (AKLI) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisInsider TradesTrendsBuy This Stock About Akili Stock (NASDAQ:AKLI) Get Akili alerts:Sign Up Key Stats Today's Range$0.43▼$0.4350-Day Range$0.42▼$0.4452-Week Range$0.19▼$1.25VolumeN/AAverage Volume2.20 million shsMarket Capitalization$34.01 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Akili, Inc., a digital medicine company, develops cognitive treatments through game-changing technologies. The company provides EndeavorRx, a computer-based testing for cognitive dysfunction across several neurology and psychiatry indications, including attention-deficit hyperactivity disorder, depressive disorder, autism spectrum disorder, multiple sclerosis, and other neuroinflammatory diseases. It also offers selective stimulus management engine mechanism to activate the fronto-parietal cortex area in the brain; body brain trainer for attention, impulsivity, working memory, and goal management; and spatial navigation engine for spatial navigation, memory, and planning and organization. The company was founded in 2011 and is headquartered in Boston, Massachusetts. Read More Receive AKLI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Akili and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AKLI Stock News HeadlinesAkili Announces FDA Authorization of EndeavorOTC, the First FDA Clearance of a Digital Treatment for Adults with ADHD Through a Video GameJune 18, 2024 | businesswire.comAKILI INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akili, Inc. - AKLIJune 14, 2024 | prnewswire.comSkip the Line Opportunity: The SpaceX IPOFormer tech executive and angel investor Jeff Brown - who identified Bitcoin, Tesla, and Nvidia before their historic runs - says the SpaceX IPO is set for June 12 and could be the most anticipated market debut ever. Brown is showing investors how to legally claim a stake before the company goes public, ahead of what chief market strategist Shay Boloor called 'the craziest IPO in the history of the stock market.'June 4 at 1:00 AM | Brownstone Research (Ad)SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AKLI, CALT, SGE on Behalf of ShareholdersJune 7, 2024 | globenewswire.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AKLI, WIRE on Behalf of ShareholdersJune 5, 2024 | globenewswire.comSHAREHOLDER INVESTIGATION: The M&A Class Action Firm Announces An Investigation of the Merger and its Tender Offer, Expiring July 31, 2024, for Shares of Akili, Inc. – AKLIJune 5, 2024 | globenewswire.comSHAREHOLDER INVESTIGATION: The M&A Class Action Firm Announces An Investigation of the Merger and its Tender Offer, Expiring July 31, 2024, for Shares of Akili, Inc. - AKLIJune 4, 2024 | prnewswire.comAKLI Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Akili, Inc. Is Fair to ShareholdersJune 3, 2024 | businesswire.comSee More Headlines AKLI Stock Analysis - Frequently Asked Questions How were Akili's earnings last quarter? Akili, Inc. (NASDAQ:AKLI) released its earnings results on Thursday, May, 11th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.18) by $0.04. The company earned $0.11 million during the quarter. Akili had a negative trailing twelve-month return on equity of 79.93% and a negative net margin of 2,492.04%. Read the conference call transcript. What other stocks do shareholders of Akili own? Based on aggregate information from My MarketBeat watchlists, some other companies that Akili investors own include Avino Silver & Gold Mines (ASM), Tesla (TSLA), Taiwan Semiconductor Manufacturing (TSM), NVIDIA (NVDA), P3 Health Partners (PIII), uniQure (QURE) and Rolls-Royce Holdings PLC (RYCEY). Company Calendar Last Earnings5/11/2023Today6/04/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolNASDAQ:AKLI CIK1850266 Webwww.akiliinteractive.com Phone650-931-6236FaxN/AEmployees130Year Founded1992Profitability EPS (Trailing Twelve Months)($0.61) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$59.49 million Net Margins-2,492.04% Pretax Margin-2,489.32% Return on Equity-79.93% Return on Assets-59.16% Debt Debt-to-Equity Ratio0.08 Current Ratio5.80 Quick Ratio5.80 Sales & Book Value Annual Sales$1.95 million Price / Sales17.46 Cash FlowN/A Price / Cash FlowN/A Book Value$0.75 per share Price / Book0.58Miscellaneous Outstanding Shares78,727,000Free Float70,776,000Market Cap$34.01 million OptionableNo Data Beta1.72 Social Links The Rise of the RobotsRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and industrial operations. This report explores the rise of “Physical AI,” highlights four key ways investors can gain exposure to the robotics revolution, and profiles seven leading companies positioned to benefit from the growing demand for intelligent automation.Get This Free Report This page (NASDAQ:AKLI) was last updated on 6/4/2026 by MarketBeat.com Staff. From Our PartnersDo NOT Buy SpaceX – Do This InsteadSpaceX is set to go public as soon as June 11, with OpenAI and Anthropic likely to follow. Whitney Tilson - Ha...Stansberry Research | SponsoredElon’s big June 12 announcementJune 12 is the reported deadline for a major announcement tied to Elon Musk's so-called 'Project Unlimited' - ...Weiss Ratings | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredTrump’s secret China dealTrump just returned from Beijing with the most powerful business delegation in American history - Elon Musk, J...Porter & Company | SponsoredGiving “2022 pre-ChatGPT” vibes (but 10x bigger)When ChatGPT launched in 2022, Nvidia surged 1,800% over three years. Now, Nvidia's CEO suggests July 22nd cou...StocksToTrade | SponsoredThe chokepoint supplier behind SpaceX's $1.75 trillion empireWhen Musk laughed and said 'you need transformers to run transformers,' it wasn't a joke - it was a confession...Behind the Markets | SponsoredThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...Banyan Hill Publishing | SponsoredWhere did Vanguard quietly put $101 billion?A new Gallup poll shows 70% of Americans want AI data centers kept out of their communities - and futurist Geo...Eagle Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akili, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akili With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
